Lifecare ASA: Mandatory notification of trade

Reference is made to the previous stock exchange announcements published by Lifecare ASA (the "Company") regarding the completion of the Rights Issue. Hannibal Invest AS, a company closely associated with Hans Hekland, board member of the Company, has 27 June 2024 subscribed 65,599 shares at a price of NOK 1,52442 per share, as compensation for the underwriting commitment made in connection with the Rights Issue. Please see the attached PDMR-form for further details. About us Lifecare ASA is a clinical stage medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's main focus is to bring the next generation of Continuous Glucose Monitoring ("CGM") systems to market. Lifecare enables osmotic pressure as sensing principle, combined with the ability to manipulate Nano-granular Tunnelling Resistive sensors ("NTR") on the sensor body for read-out of pressure variations. Lifecare's sensor technology is referred to as "Sencell" and is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets. Contacts For further information, please contact: Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40 Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42 This information is subject to disclosure under the Norwegian Securities Trading Act, §5-12. The information was submitted for publication at 2024-07-02 17:25 CEST.